Antimicrobial activity of ceftaroline tested against staphylococci with reduced susceptibility to linezolid, daptomycin, or vancomycin from U.S. hospitals, 2008 to 2011

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 7, 2013, Pages 3178-3181

  Sader, Helio S ^a   Flamm, Robert K ^a   Jones, Ronald N ^a  

^a JMI LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEFTAROLINE; DAPTOMYCIN; LINEZOLID; VANCOMYCIN;

ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; COAGULASE NEGATIVE STAPHYLOCOCCUS; DRUG SENSITIVITY; HOSPITAL; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS;

ACETAMIDES; ANTI-BACTERIAL AGENTS; CEPHALOSPORINS; DAPTOMYCIN; HOSPITALS; HUMANS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; OXAZOLIDINONES; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; VANCOMYCIN;

EID: 84879014754     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00484-13     Document Type: Article

References (22)

1. Boucher H, Miller LG, Razonable RR. 2010. Serious infections caused by methicillin-resistant Staphylococcus aureus. Clin. Infect. Dis. 51(Suppl 2): S183-S197.
2. Sader HS, Moet GJ, Farrell DJ, Jones RN. 2011. Antimicrobial susceptibility of daptomycin and comparator agents tested against methicillinresistant Staphylococcus aureus and vancomycin-resistant enterococci: trend analysis of a 6-year period in US medical centers (2005-2010). Diagn. Microbiol. Infect. Dis. 70:412-416.
3. Chua K, Laurent F, Coombs G, Grayson ML, Howden BP. 2011. Antimicrobial resistance: not community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA)! A clinician's guide to community MRSA-its evolving antimicrobial resistance and implications for therapy. Clin. Infect. Dis. 52:99-114.
4. Garau J, Bouza E, Chastre J, Gudiol F, Harbarth S. 2009. Management of methicillin-resistant Staphylococcus aureus infections. Clin. Microbiol. Infect. 15:125-136.
5. van Hal SJ, Lodise TP, Paterson DL. 2012. The clinical significance of vancomycin minimum inhibitory concentration in Staphylococcus aureus infections: a systematic review and meta-analysis. Clin. Infect. Dis. 54: 755-771.
6. Jones RN, Farrell DJ, Sader HS. 2011. Comparative activity of linezolid against respiratory tract infection isolates of Staphylococcus aureus: an 11-year report from the SENTRY Antimicrobial Surveillance Program. Int. J. Antimicrob. Agents 37:584-585.
7. File TM, Jr, Wilcox MH, Stein GE. 2012. Summary of ceftaroline fosamil clinical trial studies and clinical safety. Clin. Infect. Dis. 55(Suppl 3):S173-S180.
8. Forest Pharmaceuticals. 2012. Teflaro prescribing information. Forest Pharmaceuticals, St. Louis, MO. http://www.frx.com/pi/Teflaro-pi.pdf. Accessed January 2013.
9. Astra Zeneca. 2012. Zinforo prescribing information. Astra Zeneca, Wilmington, DE. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR- Product-Information/human/002252/WC5001325 86.pdf. Accessed December 2012.
10. Flamm RK, Sader HS, Farrell DJ, Jones RN. 2012. Summary of ceftaroline activity against pathogens in the United States, 2010: report from the Assessing Worldwide Antimicrobial Resistance Evaluation (AWARE) Surveillance Program. Antimicrob. Agents Chemother. 56:2933-2940.
11. Clinical and Laboratory Standards Institute. 2012. M2-A09. Performance standards for antimicrobial disk susceptibility tests; approved standard, 9th ed. Clinical and Laboratory Standards Institute, Wayne, PA.
12. Clinical and Laboratory Standards Institute. 2013. M100-S23. Performance standards for antimicrobial susceptibility testing: 23rd informational supplement. Clinical and Laboratory Standards Institute, Wayne, PA.
13. EUCAST. 2013. Breakpoint tables for interpretation of MICs and zone diameters. Version 3.0, January 2013. European Society of Clinical Microbiology and Infectious Diseases, Basel, Switzerland. http://www.eucast.org/clinical- breakpoints/. Accessed 2 January 2013.
14. Edelsberg J, Taneja C, Zervos M, Haque N, Moore C, Reyes K, Spalding J, Jiang J, Oster G. 2009. Trends in US hospital admissions for skin and soft tissue infections. Emerg. Infect. Dis. 15:1516-1518.
15. Diep BA, Chambers HF, Graber CJ, Szumowski JD, Miller LG, Han LL, Chen JH, Lin F, Lin J, Phan TH, Carleton HA, McDougal LK, Tenover FC, Cohen DE, Mayer KH, Sensabaugh GF, Perdreau-Remington F. 2008. Emergence of multidrug-resistant, community-associated, methicillin-resistant Staphylococcus aureus clone USA300 in men who have sex with men. Ann. Intern. Med. 148:249-257. (Pubitemid 351665484)
16. de Kraker ME, Wolkewitz M, Davey PG, Koller W, Berger J, Nagler J, Icket C, Kalenic S, Horvatic J, Seifert H, Kaasch AJ, Paniara O, Argyropoulou A, Bompola M, Smyth E, Skally M, Raglio A, Dumpis U, Kelmere AM, Borg M, Xuereb D, Ghita MC, Noble M, Kolman J, Grabljevec S, Turner D, Lansbury L, Grundmann H, Group BS. 2011. Clinical impact of antimicrobial resistance in European hospitals: excess mortality and length of hospital stay related to methicillin-resistant Staphylococcus aureus bloodstream infections. Antimicrob. Agents Chemother. 55:1598-1605.
17. Micek ST, Reichley RM, Kollef MH. 2011. Health care-associated pneumonia (HCAP): empiric antibiotics targeting methicillin-resistant Staphylococcus aureus (MRSA) and Pseudomonas aeruginosa predict optimal outcome. Medicine 90:390-395.
18. Holmes NE, Johnson PD, Howden BP. 2012. Relationship between vancomycin-resistant Staphylococcus aureus, vancomycin-intermediate S. aureus, high vancomycin MIC, and outcome in serious S. aureus infections. J. Clin. Microbiol. 50:2548-2552.
19. Pogue JM, Marchaim D, Kaye D, Kaye KS. 2011. Revisiting "older" antimicrobials in the era of multidrug resistance. Pharmacotherapy 31: 912-921.
20. Stuart JI, John MA, Milburn S, Diagre D, Wilson B, Hussain Z. 2011. Susceptibility patterns of coagulase-negative staphylococci to several newer antimicrobial agents in comparison with vancomycin and oxacillin. Int. J. Antimicrob. Agents 37:248-252.
21. Rose WE, Schulz LT, Andes D, Striker R, Berti AD, Hutson PR, Shukla SK. 2012. Addition of ceftaroline to daptomycin after emergence of daptomycin-nonsusceptible Staphylococcus aureus during therapy improves antibacterial activity. Antimicrob. Agents Chemother. 56:5296-5302.
22. Mehta S, Singh C, Plata KB, Chanda PK, Paul A, Riosa S, Rosato RR, Rosato AE. 2012. Beta-lactams increase the antibacterial activity of daptomycin against clinical methicillin-resistant Staphylococcus aureus strains and prevent selection of daptomycin-resistant derivatives. Antimicrob. Agents Chemother. 56:6192-6200.